<p>A sensitive and rapid chemiluminescence immunoassay for point-of-care testing (POCT) of copeptin in serum based on high-affinity monoclonal antibodies via cytokine-assisted immunization</p>

Abstract

Purpose: Antibodies are key reagents in the development of immunoassay. We attempted to develop high-performance CPP immunoassays using high-affinity monoclonal antibodies prepared via cytokine-assisted immunization. Methods: We used fetal liver tyrosine kinase 3 ligand (Flt3L), CC subtype chemokine ligand 20 (CCL20), and granulocyte-macrophage colony-stimulating factor (GM-CSF) to assist traditional subcutaneous immunization of preparing high-affinity monoclonal antibodies, and further to develop high-performance immunoassay methods for CPP. Results: This novel immune strategy significantly enhanced immune response against CPP. Six anti-CPP monoclonal antibodies (mAbs) with high affinity were successfully screened and selected for application in a fully automated magnetic chemiluminescence immunoassay (CLIA). This robust and rapid assay can efficiently detect CPP in the range of 1.2–1250 pmol L –1 with a detection limit of 6.25 pmol L –1 . Significantly, the whole incubation process can be completed in 30 min as compared to about 4.5 hr for the control ELISA kit. Furthermore, this assay exhibited high sensitivity and specificity, low intra-assay and inter-assay coefficients of variation (CVs < 15%). The developed assay was applied in the detection of CPP in 115 random serum samples and results showed a high correlation with data obtained using a commercially available ELISA kit (correlation coefficient, 0.9737). Conclusion: Our assay could be applied in the point-of-care testing of CPP in the serum samples, and also the method developed in this study could be adopted to explore the detection and diagnosis of other biomarkers for various diseases.

Detection of C-Reactive Protein Using Histag-HRP Functionalized Nanoconjugate with Signal Amplified Immunoassay

“…Along with improved sensitivity and simplicity, the present assay provides a reduced incubation time of around 2 h Table 1 . Classical ELISA, in general, takes about 4–5 h due to separate primary and secondary antibody incubation steps Table 1 [ 39 ].…”

Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar

“…Most published articles on this topic have focused only on the clinical outcomes of CT-P13 7 , 8 , 31 , 32 treatment, while other articles have compared patient groups who switched from the originator to the biosimilar 9 – 11 , 17 , 33 , 34 , obtaining a positive correlation between the two drugs in terms of efficacy and safety.…”

On the Challenges for the Diagnosis of SARS-CoV-2 Based on a Review of Current Methodologies

“…Most of the techniques mentioned in this review have already been employed for SARS-CoV and/or MERS-CoV, including RT-PCR, 38 ELISA, 39 LAMP, 40 CLIA, 41 LFDs, 42 immunosensors, 43 and genosensors. 44 Some have been implemented in POC devices for several pathologies, including LFDs, 45 , 46 CLIA assays, 47 genosensors, 48 electrochemical immunosensors, 43 , 49 and field-effect transistor devices. 50 Herein, we will discuss important perspectives for adapting these existing technologies for COVID-19 detection.…”